Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by askretkaon Nov 24, 2021 6:15am
335 Views
Post# 34160317

Record breaking Pharma M&A for 2022?

Record breaking Pharma M&A for 2022?
"The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. Four emerging trends back up this assertion. ------------------- First,Pfizer(NYSE:PFE)andModernaare both flush with cash thanks to their novel coronavirus vaccines. ------------------------ Second,Novartisrecently banked $21 billion after selling its two decade long position inRoche. ------------------------ Third,Amgen,AstraZeneca,Biogen,Bristol Myers Squibb,Gilead Sciences,Johnson & Johnson,Merck, Moderna, Pfizer, andSanofiare all expected to pursue bolt-on acquisitions next year to flesh out their clinical pipelines and product portfolios. ------------------------------------- Fourth,Novo Nordiskand Roche can both be counted on for at least one small to mid-sized acquisition peryear." ------------------------------------ These trends look promising fir ONC. Cheers!!!
<< Previous
Bullboard Posts
Next >>